Atrial Fibrillation with Rapid Ventricular Response Management

Primary Considerations for Rate Control

The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend that amiodarone be reserved as a second-line agent for rate control in atrial fibrillation with rapid ventricular response due to its potential for life-threatening toxicity, including pulmonary fibrosis, hepatic injury, and proarrhythmia 1
The American College of Cardiology, American Heart Association, and Heart Rhythm Society guidelines state that beta-blockers and nondihydropyridine calcium channel blockers are the drugs of choice for acute rate control in most individuals with atrial fibrillation and rapid ventricular response (Class IIa recommendation) 2

The American College of Cardiology recommends that amiodarone be considered only when conventional measures are ineffective, representing an off-label use in the United States and some other countries 1, 3
The European Society of Cardiology notes that intravenous amiodarone is effective and well-tolerated in critically ill patients with rapid atrial tachyarrhythmias refractory to conventional treatment 4

Beta-blockers, such as metoprolol, esmolol, and atenolol, are effective for acute rate control with a better safety profile, particularly useful in high adrenergic states 2, 4
Calcium channel blockers, such as diltiazem and verapamil, are effective for rapid rate control, but should be used cautiously or avoided in patients with heart failure due to systolic dysfunction 1, 2, 3

The American College of Cardiology, American Heart Association, and Heart Rhythm Society recommend considering the potential risk of conversion to sinus rhythm before treating with amiodarone in patients with atrial fibrillation duration >48 hours due to increased cardioembolic risk 2
High-dose oral amiodarone loading can worsen hemodynamics in patients with recent decompensation of heart failure or hypotension 1